Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$60.67 USD

60.67
2,198,479

-1.26 (-2.03%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $60.15 -0.52 (-0.86%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Wright Medical (WMGI) Surprise Investors in Q4 Earnings?

by Zacks Equity Research

Wright Medical Group N.V. (WMGI) is scheduled to release fourth-quarter 2016 results on Feb 21.

    Zacks Equity Research

    LabCorp (LH) Q4 Earnings: What's in the Cards for the Stock?

    by Zacks Equity Research

    Laboratory Corp. of America Holdings (LH), or LabCorp, is expected to report fourth-quarter 2016 results before the market opens on Feb 16.

      Zacks Equity Research

      What's in Store for ImmunoGen (IMGN) this Earnings Season?

      by Zacks Equity Research

      ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

        Zacks Equity Research

        Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?

        by Zacks Equity Research

        Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.

          Zacks Equity Research

          Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

          by Zacks Equity Research

          Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.

            Zacks Equity Research

            Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?

            by Zacks Equity Research

            Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.

              Zacks Equity Research

              Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

              by Zacks Equity Research

              Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

                Swarup Gupta headshot

                5 Great Biotech Stocks to Buy Now

                by Swarup Gupta

                Biotechs have stabilized and still offer the potential to deliver substantial returns.

                  Zacks Equity Research

                  BioMarin's Hemophilia Candidate Included in PRIME Initiative

                  by Zacks Equity Research

                  BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by the European Medicines Agency (EMA).

                    Zacks Equity Research

                    Is BioMarin (BMRN) Well Poised for Growth in 2017?

                    by Zacks Equity Research

                    We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

                      Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

                        Arpita Dutt headshot

                        3 Overlooked Drug Stocks to Watch Out for in 2017

                        by Arpita Dutt

                        As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.

                          Zacks Equity Research

                          BioMarin (BMRN) Raised to Buy: Should You Add the Stock?

                          by Zacks Equity Research

                          The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).

                            Indradip Ghosh headshot

                            New Strong Buy Stocks for October 24th

                            by Indradip Ghosh

                            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                              Tirthankar Chakraborty headshot

                              New Strong Buy Stocks for October 17th

                              by Tirthankar Chakraborty

                              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                                Tirthankar Chakraborty headshot

                                New Strong Buy Stocks for October 6th

                                by Tirthankar Chakraborty

                                Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                                  Zacks Equity Research

                                  5 Biotech Stocks to Bet on This Earnings Season

                                  by Zacks Equity Research

                                  The happening biotech sector should be a good bet for investors.